WO2006006269A1 - 血中中性脂肪低減剤 - Google Patents
血中中性脂肪低減剤 Download PDFInfo
- Publication number
- WO2006006269A1 WO2006006269A1 PCT/JP2005/004062 JP2005004062W WO2006006269A1 WO 2006006269 A1 WO2006006269 A1 WO 2006006269A1 JP 2005004062 W JP2005004062 W JP 2005004062W WO 2006006269 A1 WO2006006269 A1 WO 2006006269A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- blood
- heat
- neutral fat
- gauri
- reducing agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to a blood neutral fat reducing agent capable of suppressing an increase in blood neutral fat and further reducing an increased blood neutral fatty acid content. Furthermore, the present invention relates to a food or pharmaceutical composition containing the blood neutral fat reducing agent.
- Hyperlipidemia in which blood neutral fat has exceeded normal levels due to overeating, lack of exercise, and increased intake of animal fat.
- Hyperlipidemia is known to cause diseases such as arterial stiffness, hypertension, myocardial infarction, and cerebrovascular disorder.
- diseases such as arterial stiffness, hypertension, myocardial infarction, and cerebrovascular disorder.
- the amount of neutral fat in the blood It is important for modern people to suppress the increase in blood pressure and to lower the increased blood triglyceride level to the normal range. Therefore, it is desired to develop an edible material that can be ingested or administered on a daily basis and is effective in adjusting the neutral fat in the blood.
- Patent Document 1 Japanese Patent Laid-Open No. 2001-278804
- an object of the present invention is to provide a blood neutral fat reducing agent that is highly safe and can be taken or administered on a daily basis and is effective in adjusting blood neutral fat. . Furthermore, an object of the present invention is to provide foods and pharmaceuticals containing the blood neutral fat reducing agent. Means for solving the problem
- the inventors of the present invention diligently studied to solve the above-mentioned problems.
- the two-gauri heat-treated product particularly the two-gauri-heat-treated product obtained by heat-treating the two-gauri after drying, It has been found that there is an effect of reducing the amount of neutral fat in the medium.
- the present invention has been developed through further studies based on such knowledge.
- the present invention provides the following inventions:
- Item 1 A blood neutral fat reducing agent comprising heat-treated two-gauri or an extract thereof as an active ingredient.
- Item 2 The blood neutral fat reducing agent according to Item 1, wherein the two-gauri heat-treated product is obtained by drying and heating two-gauri.
- a blood neutral fat reducing agent comprising the blood neutral fat reducing agent according to Item 1 or 2, Item 4. A powder, tablet, capsule, syrup, jelly, or beverage. Food for reducing blood neutral fat according to 3.
- a pharmaceutical or quasi drug for reducing blood neutral fat comprising the blood neutral fat reducing agent according to Item 1 or 2.
- a two-gauri heat-treated product is used as an active ingredient.
- Nigauri is a cucurbitaceae plant known as the scientific name Momordica charantia and is native to tropical Asia. Nigauri is also known as Goyallreishi. The bigauri used in the present invention may be a wild species or an improved variety.
- a fruit part of 2-gauri is used as a raw material of the heat-treated 2-gauri product which is the active ingredient of the present invention.
- the fruit part includes fruit skin, fruit pulp, fruit juice, cotton, seeds, etc., but any of these parts may be used as a raw material for the two-gauri heat-treated product.
- it is an edible part obtained by removing seeds and cotton from the fruit part, and more preferably pulp.
- the two-gauri heat-treated product is chopped or crushed as necessary, for example, 40-1
- the two-gauri heat-treated product is preferably obtained by heating the two-gauli after drying.
- a method for preparing a two-gauli heat-treated product by drying and heating the two-gauri will be described.
- the preparation of heat-treated cucumber garlic it is subjected to a process of drying garlic prior to heat treatment of garlic, but before the drying process, the garlic is shredded or crushed to an appropriate size. It is desirable to keep it. From the viewpoint of efficiently performing drying and heating, it is desirable to cut the two gourd into pieces of about 120 mm, preferably about 5-8 mm.
- the dry weight of bigauri may be carried out until the weight is reduced to 120%, preferably 5-12% of the weight before drying.
- the drying method and conditions are not particularly limited, and a drying method known or commonly used in the art may be employed.
- Specific examples of the drying method include a method of drying by applying hot air of about 40 to 120 ° C, and a method of drying for 15 to 15 days in the sun, preferably about 3 days.
- the dried bigauri is then subjected to a heat treatment (for example, roasting treatment).
- the calorific heat condition is appropriately adjusted according to the heating temperature and the heating time.
- the heating temperature is usually set to 40-120 ° C, preferably 60-120 ° C.
- the heating time varies depending on the heating temperature and cannot be specified uniformly, but is usually 1 to 60 minutes, preferably about 3 to 15 minutes.
- the heating method is not particularly limited, and an example of a suitable heating method is a method of frying under the above temperature conditions.
- the said heat processing can be implemented using a roasting machine etc., for example.
- a two-gauri heat-treated product is prepared.
- the heat-treated product of two-gauri is usually reduced to a weight of 1-10%, preferably 5-7% of the weight of 2-gauri before drying.
- An extract of a heat-treated 2-gauli product can be obtained by extracting a heat-treated product of 2-gauri with an extraction solvent at room temperature or under heating.
- the extraction solvent include water; an organic solvent; or a mixed solution of water and an organic solvent.
- an organic solvent used for extraction examples include methanol, ethanol, isopropanol, propylene glycol, 1,3-butylene glycol, acetone, ethyl acetate, chloroform, pentane, hexane, heptane and the like alone or in combination of two or more.
- the extraction solvent is preferably water; a lower alcohol such as methanol, ethanol or isopropanol; or a mixture of water and a lower alcohol, more preferably water, ethanol or a mixture of water and ethanol (5-50).
- a water-weight ethanol solution particularly preferably water.
- the above water includes warm water and hot water.
- the extract of the bigauri heat-treated product used in the blood neutral fat reducing agent may be the extract obtained by the above-described extraction treatment as it is, or a solid substance from the extract. (Insoluble matter) may be removed. Further, if necessary, it may be further concentrated by vacuum distillation or the like, or may be dried by a drying process such as vacuum drying or freeze drying.
- the intake or dose of the blood triglyceride reducing agent of the present invention varies depending on the age, sex, expected effect, etc. of the subject and cannot be uniformly defined, As an example of ingestion or dosage, 0.1 to 4 g, preferably 0 to 3 to 2 g, more preferably 0 to 7- An amount of 2g is illustrated.
- the blood triglyceride reducing agent of the present invention can also be provided as a food for reducing blood triglycerides by mixing with food, and can also be prepared in the form of pharmaceuticals or quasi drugs. Thus, it can also be provided as a pharmaceutical or quasi-drug for reducing blood neutral fat.
- the food for reducing blood neutral fat is preferably a health functional food (functional nutrition food and food for specified health use), so-called health food, dietary supplement or special food (food for patients, etc.) ) And the like.
- a health functional food functional nutrition food and food for specified health use
- health food dietary supplement or special food (food for patients, etc.)
- the form include powders, tablets, capsules, syrups, jelly and the like.
- the extract of the two gourd heat-treated product obtained using water as an extraction solvent can be used as it is, the extract itself, or a concentrated or diluted solution thereof may be used as a beverage-type food.
- the ratio of the blood neutral fat reducing agent to be blended depends on the daily intake of the agent, the form of the food, the expected effect, etc. Appropriate settings may be made accordingly.
- the shape of the pharmaceutical or quasi-drug for reducing blood neutral fat is not particularly limited as long as the effect of the present invention is not hindered.
- Examples of the form of the pharmaceutical product or quasi drug include tablets, powders, granules, capsules, pills, troches, liquids, extracts and the like.
- the drug or quasi-drug is formulated with a pharmaceutically acceptable carrier or carrier, but if necessary, a binder, disintegrant, lubricant, wetting agent, buffer, storage Pharmaceutically acceptable additives such as agents and fragrances may be optionally contained.
- the ratio of the neutral fat-reducing agent contained in the above-mentioned pharmaceutical or quasi-drug for reducing blood neutral fat is the dose of the agent per day, the age and sex of the subject, the pharmaceutical or pharmaceutical It can be appropriately set according to the form of the quasi-drug, the expected effect, and the like.
- the blood triglyceride reducing agent of the present invention can suppress an increase in blood triglyceride and can further reduce the blood triglyceride content. Therefore, the blood neutral fat reducing agent of the present invention is useful as an agent for preventing or improving hyperlipidemia.
- the blood triglyceride reducing agent of the present invention is also useful as a preventive or ameliorating agent for diseases in which onset or deterioration of symptoms is expected due to abnormal blood triglyceride content. is there.
- Specific examples of powerful diseases include myocardial infarction, arteriosclerosis, angina pectoris, thrombosis, and cerebral infarction. Therefore, according to the blood neutral fat reducing agent of the present invention, it is possible to prevent sudden death due to myocardial infarction or arterial stiffness.
- the blood neutral fat reducing agent of the present invention is useful as a sebum secretion inhibitor because it can suppress the secretion of sebum based on the effect of reducing blood neutral fat. is there. Therefore, the blood neutral fat reducing agent of the present invention can exert a facial shine prevention action based on suppression of sebum secretion in the face and a hair growth action based on suppression of sebum accumulation in the scalp.
- the blood triglyceride reducing agent of the present invention an increase in blood triglyceride can be suppressed, and the elevated blood triglyceride content can be reduced.
- the amount of neutral fat can be adjusted. Therefore, the blood triglyceride reducing agent of the present invention is useful for the prevention and improvement of diseases caused by abnormal blood triglycerides.
- the blood neutral fat reducing agent of the present invention has been conventionally used as a raw material for foods. It can be taken or administered on a daily basis as a highly safe food or pharmaceutical because it is prepared using gauri as a raw material.
- the two-gauli heat-treated product obtained by drying and heating two-gauri does not have the bitterness peculiar to two-gauri and does not adversely affect the taste.
- the reducing agent can be used without being limited by the type of food or the form of the pharmaceutical or pharmaceutical composition, and can provide a wide variety of means for reducing blood neutral fat.
- the chopped Nigauri lOOOOg was dried with a hot air dryer at 40 120 ° C hot air until the weight reached 120 g.
- the iron plate temperature was gradually raised from 70 ° C. to 110 ° C. for 15 minutes and fried to obtain 60 g of a two-gauri heat-treated product.
- the 2-gauli heat-treated product thus obtained was added to hot water immediately after boiling, and left to stand for 1 minute, and extracted so that the 2-gauri-heat-treated product was 0.2 g per 100 g of the extract. Thereafter, an extract from which solid residue was removed by filtration was used as a test sample.
- the amount of sebum secreted in the forehead was measured by subjects who took the test sample under the conditions shown in Table 1 below. Specifically, using oil blotting paper (trade name “Makeh Planetary Oil Blotting Paper”, manufactured by Orbit Co., Ltd., 100% natural hemp), the subject's forehead sebum is sufficient. Sucked up. Immediately thereafter, about 300 g of grilled meat was ingested. Two hours after the disclosure of the grilled meat intake, the oil on the left half of the subject's left forehead was thoroughly blotted using oil blotting paper. Furthermore, 4 hours after the disclosure of grilled meat intake, the oil on the right half of the subject's forehead was sufficiently absorbed using oil blotting paper again. The amount of sebum 2 and 4 hours after ingestion of yakiniku was calculated according to the following formula.
- Sebum amount (g) (weight of oil blotting paper after absorbing sebum) (g)
- Table 2 shows the results obtained.
- the rate of decrease in sebum secretion means the ratio (%) of the amount of sebum that has decreased relative to the amount of sebum in the control.
- the amount of sebum secreted in the forehead is reduced by ingesting the extract of the two-gauri heat-treated product.
- the amount of sebum secreted could be significantly reduced by daily intake of the extract of the heat-treated two gourd.
- the heat-treated two-gauri food or its extract has an action of suppressing the increase in the amount of neutral fat in the blood. It became clear that it can be improved to a constitution with less fat.
- Test Examples 1 and 2 show the average of the results of all subjects.
- Example 2 (capsule)
- the capsule body part is filled with 200 mg of the two-gauli heat-treated product prepared by the method described in Example 1. Then, the cap part was combined to prepare a capsule containing the two-gauri heat-treated product.
- a soft drink having the following composition was prepared.
- Extract of Nigauri heat-treated product prepared by the method described in Example 1
- Fructose dextrose liquid sugar 6.0
- Sodium citrate 0.6
- a jelly having the following composition was prepared.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004280319 | 2004-09-27 | ||
| JP2004-280319 | 2004-09-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2006006269A1 true WO2006006269A1 (ja) | 2006-01-19 |
| WO2006006269A8 WO2006006269A8 (ja) | 2006-03-02 |
Family
ID=35783631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2005/004062 Ceased WO2006006269A1 (ja) | 2004-09-27 | 2005-03-09 | 血中中性脂肪低減剤 |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2006006269A1 (ja) |
-
2005
- 2005-03-09 WO PCT/JP2005/004062 patent/WO2006006269A1/ja not_active Ceased
Non-Patent Citations (2)
| Title |
|---|
| HARADA H. ET AL: "Inhibition of Glycation by Momordica charantia L. and Its Influence on Lipid Metabolizing Enzymes in Streptozotocin-induced Diabetic Rats", ITE LETTERS ON BATTERIES, NEW TECHNOLOGIES & MEDICINE, vol. 3, no. 6, 2002, pages 727 - 731, XP002996089 * |
| WATANABE M. ET AL: "Tonyobyo Rat no Shishitsu Taisha no Oyobosu Nigauri Funmatsu choseiji ni Okeru kanso Shori Hoho no Eikyo", NIPPON SHOKUHIN KAGAKU KOGAKU TAIKAI KOENSHU, vol. 50, 2003, pages 67, XP002996088 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006006269A8 (ja) | 2006-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101370841B1 (ko) | 구아바 잎 엑기스 분말 및 그의 제조방법 | |
| EP3154362A1 (en) | Green coffee bean extract and method thereof | |
| CN105169203B (zh) | 一种砂仁提取物及其用途 | |
| EP0930019A2 (en) | Composition for treating obesity and foods and drinks containing the same | |
| JP4358957B2 (ja) | フリーラジカル又は活性酸素を消去もしくは低減する剤 | |
| CN103070279B (zh) | 一种功能因子强化酥心糖及其加工方法 | |
| JP2011032217A (ja) | 脂肪吸収抑制剤 | |
| JP2022031912A (ja) | 経口組成物 | |
| JP7007663B2 (ja) | クロモジ抽出物 | |
| CN106993697A (zh) | 一种红糖姜茶及其制作工艺 | |
| CN103330175B (zh) | 一种天然植物组合物调味品及其制备方法 | |
| JP2005185188A (ja) | アセロラ処理物およびl−カルニチン含有組成物 | |
| EP1583547A1 (en) | Anti-obesity ingretients from medicinal plants and their composittion | |
| JP3628999B2 (ja) | 苦瓜茶及びその製造方法 | |
| KR20220000892A (ko) | 새싹보리 추출물을 포함하는 남성 갱년기 증후군 예방 또는 치료용 조성물 | |
| JP5131895B2 (ja) | シークワーシャー由来の脂質代謝改善剤 | |
| CN106999532A (zh) | 含有复合提取物的运动执行能力增强及体力增进用组合物 | |
| JP2013035771A (ja) | 沈香葉組成物、及びその製造方法、並びに沈香葉抽出物の製造方法 | |
| KR20210115294A (ko) | 밀싹 추출물을 포함하는 남성 갱년기 증후군 예방 또는 치료용 조성물 | |
| WO2006006269A1 (ja) | 血中中性脂肪低減剤 | |
| JP2004352626A (ja) | 植物由来成分を含有する抗コレステロール剤 | |
| WO2014134833A1 (zh) | 可食用组合物及其制备方法和包含该组合物的食品 | |
| JP2006117658A (ja) | 血中中性脂肪低減剤 | |
| WO2006006270A1 (ja) | 脱毛改善剤 | |
| CN106998723A (zh) | 美藤果油在调节动物肠道菌群中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| WR | Later publication of a revised version of an international search report | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |